Table 1.
Characteristics of patients included studies. “-” means that it cannot be obtained from the full text.
| Study | Patients(n) | Age | Female ratio | BMI (kg/m2) | Type of fracture | Type of treatment | bisphosphonates | Follow-up time |
|---|---|---|---|---|---|---|---|---|
| Adolphson. ( 25 ) | 32 | 62(50-76) | 100% | – | Colles | closed reduction | Clodronate | 8 weeks |
| Altintaş, F. ( 26 ) | 46 | – | – | – | Hip Fracture | Surgery | risedronate | 3 months |
| Cecilia, D. ( 27 ) | 239 | 81 ± 7 | 79.8% | 25.3 | Hip fracture | Surgery | alendronate | 1 years |
| Colón-Emeric, C. S. ( 28 ) | 537 | – | 76.1% | 24.7 | Hip Fracture | Surgery | Zoledronic acid | 1.9 years |
| Gong, H. S. ( 29 ) | 50 | >50 | 100% | – | Distal Radial Fractures | Surgery | several | 3 months |
| Harding, A. K. ( 30 ) | 46 | 49 (37–63) | 21.7% | 27.1 | OA high tibial osteotomies | hemicallotasis technique | Zoledronic acid | 1.5 years |
| Kim, T. Y. ( 31 ) | 51 | – | – | – | intertrochanteric fractures | Surgery | risedronate | 1 year |
| Li, C. ( 32 ) | 82 | 63.73 ± 6.03 | 64.6% | 22.89 | Lumbar | TLIF surgery | Zoledronic acid | 1 year |
| Reid, I. R. ( 33 ) | 1367 | 75.8 | 90.1% | – | Hip Fracture | Surgery | Zoledronic acid | 1 year |
| Rozental, T. ( 34 ) | 196 | 69.0 | 79.1% | – | Distal Radial Fractures | several | Alendronate & risedronate | 1 year |
| Sato, Y. ( 35 ) | 80 | 75(70-79) | 100% | – | Hip Fracture | Surgery | Etidronate | 3 months |
| Shi, C. ( 36 ) | 63 | 77.14 | 46.0% | 30.95 | OVCF | PKP surgery | Zoledronic acid | 2 years |
| Uchiyama, S. ( 37 ) | 80 | 70.1 | 38% | – | Distal Radial Fractures | Surgery | alendronate | 6months |
| van der P. ( 38 ) | 41 | 46.0 | 43.9% | 25.2 | Lower Leg fracture | Surgery | Alendronate | 1 year |
| Zhang, J. ( 39 ) | 101 | 64.29 | 43.9% | 26.1 | Lumbar | Surgery | Zoledronic acid | 1 year |
| Duckworth, A. D. ( 40 ) | 421 | 63.4 | 86% | – | Distal Radial Fractures | several | Alendronate | 6months |